481例肺结核患者原始耐药监测  

Surveillance of primary resistance in 481 cases of pulmonary tuberculosis

作　　者：甄新安[1] 姚莲英[1] 彭义利[1] 王国斌[1] 徐吉英[1] 杜思和[1] 

机构地区：[1]河南省结核病防治研究所,郑州450003

出　　处：《中华结核和呼吸杂志》1999年第6期362-363,共2页Chinese Journal of Tuberculosis and Respiratory Diseases

摘　　要：目的了解河南省结核分支杆菌原始耐药情况，制定科学的防治对策。方法采用WHO制定的结核分支杆菌耐药监测方案开展河南省结核分支杆菌耐药监测，使用比例法对481例新发现无抗结核用药史的菌阳肺结核患者的耐药性进行测定。结果各药的原始耐药率分别为：H22．7％，R15．8％，522．7％，E7．7％；原始耐多药率分别为：HR2．3％，HRS5．0％，HRE0．4％，HRS5．4％。结论河南省结核分支杆菌原始耐药现状严重，实施抗结核药统一管理、全程督导化疗（DOTs）势在必行。To understand the primary resistance of Mycobacterium tuberculosis in Henan province,and to make scientific prophylactic and treatment strategies Methods Drug resistance surveillance (DRS) was implemented in Henan province according to WHO/IUATLD Guidelines for Surveillance of Drug Resistance in Tuberculosis (1994), and proportional method was used to detect primary resistance in 481 new cases ofbacillus-positive pulmonary tuberculosis without history of anti-tuberculosis drug use.Results The primary drugresistance(PDR) rates were 22.7% , 15.8%, 22.7% and 7.7% for INH, RFP, SM and EMB,respectively.The primaxy multi-drug resistance (MDR) rates were 2.3%, 5.0%, 0.4% and 5.4% for HR, HRS, HRE and HRSE, respectively,Conclusions The resuits show that the problem of primary resistance of Mycobacterium tuberculosis is serious in Henan province,and uniform management of anti-tuberculosis drugs and implementation of DOTs are needed.

关 键 词：肺结核 药物疗法 抗药性 监测 

分 类 号：R521.05[医药卫生—内科学]